Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2007-09-25
2011-12-20
Mosher, Mary E (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S006130, C435S032000
Reexamination Certificate
active
08080370
ABSTRACT:
An easy and efficient screening method for an agent useful for prevention and/or treatment of hepatitis C virus-related disease, and a prophylactic and/or therapeutic agent for hepatitis C virus-related disease obtained by the method. The screening method comprises a step of examining the inhibitory activity of an test substance on the protein-protein interaction between hepatitis C virus core protein and PA28.gamma,. The method can be carried out by using transcriptional activity of a lipid metabolism-control factor as indicator. The test substance used in the method may have an activity to inhibit expression or function of the PA28.gamma. gene. The hepatitis C virus-related diseases include fatty liver, acute hepatitis, chronic hepatitis, liver cirrhosis, liver cancer, and insulin-resistant diseases. The method is extremely useful as a method of obtaining an agent superior in preventive and therapeutic activity particularly to diseases such as fatty liver and liver cancer.
REFERENCES:
patent: WO-2006/021896 (2006-03-01), None
Wojcik (International Journal of Biochemistry & Cell Biology 1999:273-276, 1999).
Moriishi et al (Journal of Virology 77:10237-10249, 2003).
Moriishi et al (PNAS 104:1661-1666, 2007).
Karimova et al (International Journal of Medical Microbiology 292:17-25, 2002).
Yoshikawa et al (Journal of Biological Chemistry 277:1705-1711, 2002).
Matsuura et al (The Japanese Cancer Association Gakujutsu Shokai Kiji, 65, Aug. 2006, p. 75).
Kyoji Moriya et al., “The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice,” Nature Medicine 4, 1998, pp. 1065-1067.
L.-R. You et al., “Hepatitis C Virus Core Protein Interacts with Cellular Putative RNA Helicase,” J. Virol. 73: 1999, pp. 2841-2853.
M. Otsuka et al., “Hepatitis C Virus Core Protein Enhances p53 Function through Augmentation of DNA Binding Affinity and Transcriptional Ability,” J. Biol. Chem. 275: 2000, pp. 34122-34130.
T. Yoshida et al., “Activation of STAT3 by the Hepatitis C Virus Core Protein leads to Cellular Transformation,” J. Exp. Med. 196: 2002, pp. 641-653.
K. Moriishi et al., “Proteasome Activator PA28γ-Dependent Nuclear Retention and Degradation of Hepatitis C Virus Core Protein,” J. Virol., 77, 19, 2003, pp. 10237-10249.
D-Y Jin et al., “Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation,” EMBO J. 19: 2000, pp. 729-740.
A. Alisi et al., “Physical and functional interaction between HCV core protein and the different p73 isoforms,” Oncogene 22(17): 2003, pp. 2573-2580.
K. Watashi et al., “Modulation of Retinoid Signaling by a Cytoplasmic Viral Protein via Sequestration of Sp110b, a Potent Transcriptional Corepressor of Retinoic Acid Receptor, from the Nucleus,” Mol. Cell Biol. 23(21): 2003, pp. 7498-7509.
M. Gomez-Gonzalo et al., “Hepatitis C virus core protein regulates p300/CBP co-activation function. Possible role in the regulation of NF-AT1 transcriptional activity,” Virology 328(1): 2004, pp. 120-30.
R-T Mai et al., “Hepatitis C virus core protein recruits nucleolar phosphoprotein B23 and coactivator p300 to relieve the repression effect of transcriptional factor YY1 on B23 gene expression,” Oncogene Jan. 19; 25 (3): 2006, pp. 448-462.
Y. Matsuura et al., “Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis,” The Japanese Cancer Association Gakujutsu Shokai Kiji, 65, 2006, 2 sheets including p. 75.
K. Moriishi et al., Proteasome activator PA28γ-dependent nuclear retention and degradation of hepatitis C virus core protein. J. Virol, 77, 2003, pp. 10237-10249.
M. Rechsteiner et al., “Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors,” Trends in Cell Biology, 15, 2003, pp. 27-33.
K. Moriishi et al., “Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis,” Proc. Natl. Acad. Sci. USA, 104, 2007, pp. 1661-1666.
International Search Report mailed Dec. 25, 2007, issued on PCT/JP20071069155.
Natalia A. Osna et al., “Hepatitis C virus core protein activates proteasome function by induction of oxidative stress in liver cells,” Hepatology, vol. 44, No. 4, Suppl. 1, Oct. 2006, p. 584A.
Supplementary Partial European Search Report dated Mar. 26, 2010, issued on the European patent application No. 07828895.8.
Matsuura Yoshiharu
Moriishi Kohji
Edwards Wildman Palmer LLP
Mosher Mary E
Osaka University
LandOfFree
Screening method for prophylactic and/or therapeutic agent... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Screening method for prophylactic and/or therapeutic agent..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening method for prophylactic and/or therapeutic agent... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4259348